Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
- Mechanism
- Curator reviewed
S-transferase P1-1 (GST P1-1) is an enzyme overexpressed in many human cancer cells. High levels of GST P1-1 are associated with a poor prognosis and resistance to certain chemotherapeutics. The activation of canfosfamide occurs when GST P1-1 splits canfosfamide into two active fragments: a glutathione analog fragment and an active cytotoxic fragment. The cytotoxic fragment reacts with important cell components, including RNA, DNA and proteins, leading to cell death. The glutathione analog fragment of canfosfamide may remain bound to GST P1-1, which may limit the ability of GST P1-1 to inactivate other cancer drugs.
- Primary indication
- Intended for the treatment of various forms of cancer.Curator reviewed
- Formula / weight
- C26H40Cl4N5O10PS · 787.46 g/mol (avg)
Resolves to
OJLHWPALWODJPQ-QNWVGRARSA-NSMILESN[C@@H](CCC(=O)N[C@@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1)C(O)=OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Canfosfamide, and which of those have an active Phase 3 trial?